A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment

Response rate and toxicity of second-line therapy with docetaxel (75 mg m(−2)) or docetaxel, irinotecan, and lenogastrim (60 mg m(−2), 200 mg m(−2), and 150 μg m(−2) day(−1), respectively) were compared in 108 patients with stage IIIb–IV non-small-cell lung cancer. Addition of irinotecan to docetaxe...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Wachters, F M, Groen, H J M, Biesma, B, Schramel, F M N H, Postmus, P E, Stigt, J A, Smit, E F
Format: Artigo
Langue:Inglês
Publié: Nature Publishing Group 2005
Sujets:
Short Communication
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361740/
https://ncbi.nlm.nih.gov/pubmed/15597104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602268
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires